Bharat Biotech expects WHO approval for Covaxin by July-Sep


Hyderabad, May 25 | Bharat Biotech has said on Tuesday that it is expecting regulatory approvals from the World Health Organisation (WHO) for its Covid-19 vaccine Covaxin by July-September 2021.

The Hyderabad-based company stated that application for Emergency Use Listing (EUL) has been submitted to WHO, Geneva and regulatory approvals are expected by July-September 2021.

It also said regulatory approvals for Covaxin are in process in more than 60 countries including the United States, Brazil and Hungary.

“Emergency use authorisations have been obtained in 13 countries with more to follow,” it said.

Most countries recommend vaccinations against Covid-19. Unvaccinated travellers can travel with negative RT-PCR tests prior to travel, in the absence of any other country specific travel restrictions, it added.

Bharat Biotech’s statement came out amid reports that people who have taken Covaxin and plan to travel abroad were nervous as it is not in the list of WHO approved vaccines.

With countries gearing up to resume travel and tourism, intending travellers from India who have taken Covaxin jabs will be anxiously waiting for Covaxin’s approval by WHO.

Pfizer, Moderna and Covishield are on WHO’s approved list and people who have taken these vaccines may not face any restrictions while travelling. Those who have taken vaccines which are not on the approved list of WHO may have to undergo quarantine on landing in the destination countries.

Bharat Biotech is reported to have submitted 90 per cent of the documentation to the WHO for EUL.

WHO’s EUL is expected to open the doors for Covaxin to be accepted by countries around the world.

Covaxin and Covishield are the two vaccines which are currently included in the Covid vaccination programme in India. Russia’s Sputnik is soon likely to join the vaccination drive.

In January, India’s drug regulator had approved Covaxin for emergency use but the move came under criticism as the full data from its clinical trials was not available. This was believed to be one of the reasons for vaccine hesitancy among the target groups in the initial stages of the vaccine drive.

Bharat Biotech and the Indian Council of Medical Research (ICMR) claimed last month that Covaxin had shown overall interim effectiveness of 78 per cent.

Source: IANS

Next Story

Does MBA really help in getting a better job offer ?

Does MBA really help in getting a better job offer ?

Most students pursuing an MBA come with the sole objective of having a decent job offer or a promotion in the existing job soon after completion of the MBA. And most of them take loans to pursue this career dream. According to a recent survey by education portal  74% MBA 2022-24 aspirants said they would opt for education loans.

There are exceptional cases like those seeking master’s degree or may have a family business to take care of or an entrepreneurial venture in mind. But the exception cases are barely 1%. For the rest 99%, a management degree is a ticket to a dream job through campus placements or leap towards career enhancements. Stakes are high as many of them quit their jobs which essentially means loss of 2 years of income, apprehension and uncertainty of the job market. On top of that, the pressure to pay back the education loans. Hence the returns have to be high. There is more than just the management degree. Colleges need to ensure that they offer quality management education which enables them to be prepared for not just the demands of recruiters and for a decent job but also to sustain and achieve, all along their career path.

  • So, what exactly are the B Schools doing to prepare their students for the job market and make them industry ready ?
  •  Are B schools ready to deliver and prepare the future business leaders to cope up with the disrupted market ?  

These are the two key questions every MBA aspirant needs to ask, check and validate before filling the MBA application forms of management institutes. And worth mentioning that these application forms do not come cheap. An MBA aspirant who may have shortlisted 5 B Schools to apply for, may end up spending Rs 10,000.00 to Rs 15,000.00 just buying MBA / PGDM application forms.

While internship and placements data of some management institutes clearly indicates that recruiters today have specific demands. The skill sets looked for are job centric and industry oriented. MBA schools which have adopted new models of delivery and technology, redesigned their courses, built an effective evaluation process and prepared the students to cope with the dynamic business scenario, have done great with campus placements despite the economic slow down.

However, the skill set being looked for by a consulting company like Deloitte or KPMG may be quite different from FMCG or a manufacturing sector. Institutes need to acknowledge this fact and act accordingly.

  • Management institutes should ensure that students are intellectually engaged, self motivated and adapt to changes fast. In one word ‘VUCA ready’.
  • B Schools should encourage students to participate in national and international competitive events, simulations of business scenarios.
  • Institutes should have the right mix of faculty members with industry exposure and pure academics.

The placement records of 2021 across top management institutes indicated the fact that recruitment is happening, skilled talent is in demand and certain management institutions continued to attract recruiters even in the middle of an ongoing crisis.

It is time, all management institutes rise to the occasion, understand market realities and identify areas of improvement at both ends – students and faculty.

After all, the stakes are high at both ends. B Schools taking corrective measures will stay while those which are lagging will end up shutting down.

Author Name : Nirmalya Pal


Please enter your comment!
Please enter your name here